DOI QR코드

DOI QR Code

Cancer of the Anal Canal: Diagnosis, Staging and Follow-Up with MRI

  • Durot, Carole (Department of Radiology, Centre Hospitalo-Universitaire de Reims) ;
  • Dohan, Anthony (Department of Abdominal Imaging, Hopital Lariboisiere-APHP) ;
  • Boudiaf, Mourad (Department of Abdominal Imaging, Hopital Lariboisiere-APHP) ;
  • Servois, Vincent (Department of Radiology and Nuclear Medicine, Institut Curie) ;
  • Soyer, Philippe (Department of Abdominal Imaging, Hopital Lariboisiere-APHP) ;
  • Hoeffel, Christine (Department of Radiology, Centre Hospitalo-Universitaire de Reims)
  • Received : 2017.01.19
  • Accepted : 2017.03.26
  • Published : 2017.12.01

Abstract

Although a rare disease, anal cancer is increasingly being diagnosed in patients with risk factors, mainly anal infection with the human papilloma virus. Magnetic resonance imaging (MRI) with external phased-array coils is recommended as the imaging modality of choice to grade anal cancers and to evaluate the response assessment after chemoradiotherapy, with a high contrast and good anatomic resolution of the anal canal. MRI provides a performant evaluation of size, extent and signal characteristics of the anal tumor before and after treatment, as well as lymph node involvement and extension to the adjacent organs. MRI is also particularly helpful in the assessment of complications after treatment, and in the diagnosis for relapse of the diseases.

Keywords

References

  1. American Joint Committee on Cancer. AJCC cancer staging manual, 7th ed. New York: Springer, 2010:103-106
  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300 https://doi.org/10.3322/caac.20073
  3. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281-288 https://doi.org/10.1002/cncr.20364
  4. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist 2007;12:524-534 https://doi.org/10.1634/theoncologist.12-5-524
  5. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375-2383 https://doi.org/10.1002/ijc.24215
  6. Barral M, Dohan A, Allez M, Boudiaf M, Camus M, Laurent V, et al. Gastrointestinal cancers in inflammatory bowel disease: an update with emphasis on imaging findings. Crit Rev Oncol Hematol 2016;97:30-46 https://doi.org/10.1016/j.critrevonc.2015.08.005
  7. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-1054 https://doi.org/10.1016/S0140-6736(96)03409-5
  8. Peiffert D, Tournier-Rangeard L, Gerard JP, Lemanski C, Francois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012;30:1941-1948 https://doi.org/10.1200/JCO.2011.35.4837
  9. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921 https://doi.org/10.1001/jama.299.16.1914
  10. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-2539 https://doi.org/10.1200/JCO.1996.14.9.2527
  11. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-2049 https://doi.org/10.1200/JCO.1997.15.5.2040
  12. Sjodahl RI, Myrelid P, Soderholm JD. Anal and rectal cancer in Crohn's disease. Colorectal Dis 2003;5:490-495 https://doi.org/10.1046/j.1463-1318.2003.00510.x
  13. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii10-20 https://doi.org/10.1093/annonc/mdu159
  14. Matalon SA, Mamon HJ, Fuchs CS, Doyle LA, Tirumani SH, Ramaiya NH, et al. Anorectal cancer: critical anatomic and staging distinctions that affect use of radiation therapy. Radiographics 2015;35:2090-2107 https://doi.org/10.1148/rg.2015150037
  15. Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, et al. Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer 2015;15:281 https://doi.org/10.1186/s12885-015-1244-7
  16. Kochhar R, Renehan AG, Mullan D, Chakrabarty B, Saunders MP, Carrington BM. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. Eur Radiol 2017;27:607-617 https://doi.org/10.1007/s00330-016-4337-z
  17. Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys 2010;78:715-721 https://doi.org/10.1016/j.ijrobp.2009.08.055
  18. Koh DM, Dzik-Jurasz A, O'Neill B, Tait D, Husband JE, Brown G. Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol 2008;81:91-98 https://doi.org/10.1259/bjr/96187638
  19. Jederan E, Lovey J, Szentirmai Z, Hitre E, Lerant G, Horvath K, et al. The role of MRI in the assessment of the local status of anal carcinomas and in their management. Pathol Oncol Res 2015;21:571-579 https://doi.org/10.1007/s12253-014-9857-8
  20. Beets-Tan RG, Lambregts DM, Maas M, Bipat S, Barbaro B, Caseiro-Alves F, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2013;23:2522-2531 https://doi.org/10.1007/s00330-013-2864-4
  21. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM. Magnetic resonance imaging of anal cancer. Clin Radiol 2005;60:1111-1119 https://doi.org/10.1016/j.crad.2005.05.008
  22. Gourtsoyianni S, Goh V. MRI of anal cancer: assessing response to definitive chemoradiotherapy. Abdom Imaging 2014;39:2-17 https://doi.org/10.1007/s00261-013-0032-6
  23. Kochhar R, Plumb AA, Carrington BM, Saunders M. Imaging of anal carcinoma. AJR Am J Roentgenol 2012;199:W335-W344 https://doi.org/10.2214/AJR.11.8027
  24. Cotter SE, Grigsby PW, Siegel BA, Dehdashti F, Malyapa RS, Fleshman JW, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006;65:720-725 https://doi.org/10.1016/j.ijrobp.2006.01.009
  25. Mistrangelo M, Pelosi E, Bello M, Ricardi U, Milanesi E, Cassoni P, et al. Role of positron emission tomographycomputed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 2012;84:66-72 https://doi.org/10.1016/j.ijrobp.2011.10.048
  26. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 2009;100:693-700 https://doi.org/10.1038/sj.bjc.6604897
  27. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th ed. Toronto: Wiley Blackwell, 2016:77
  28. Otto SD, Lee L, Buhr HJ, Frericks B, Hocht S, Kroesen AJ. Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg 2009;13:1292-1298 https://doi.org/10.1007/s11605-009-0870-2
  29. Parikh J, Shaw A, Grant LA, Schizas AM, Datta V, Williams AB, et al. Anal carcinomas: the role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up. Eur Radiol 2011;21:776-785 https://doi.org/10.1007/s00330-010-1980-7
  30. Hama Y, Makita K, Yamana T, Dodanuki K. Mucinous adenocarcinoma arising from fistula in ano: MRI findings. AJR Am J Roentgenol 2006;187:517-521 https://doi.org/10.2214/AJR.05.0011
  31. Singer M, Mutch MG. Anal melanoma. Clin Colon Rectal Surg 2006;19:78-87 https://doi.org/10.1055/s-2006-942348
  32. Rousset P, Hoeffel C. [Tumors of the rectum: MRI and CT features]. J Radiol 2007;88(11 Pt 1):1679-1687 https://doi.org/10.1016/S0221-0363(07)74046-5
  33. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:449-454 https://doi.org/10.6004/jnccn.2012.0046
  34. Steele SR, Varma MG, Melton GB, Ross HM, Rafferty JF, Buie WD; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2012;55:735-749 https://doi.org/10.1097/DCR.0b013e318255815e
  35. Renehan AG, O'Dwyer ST. Management of local disease relapse. Colorectal Dis 2011;13 Suppl 1:44-52 https://doi.org/10.1111/j.1463-1318.2010.02500.x
  36. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, et al. Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology 2005;52:780-784
  37. Hoeffel C, Mule S, Laurent V, Pierredon-Foulogne MA, Soyer P. Current imaging of rectal cancer. Clin Res Hepatol Gastroenterol 2015;39:168-173 https://doi.org/10.1016/j.clinre.2014.07.014

Cited by

  1. Ischiorectal fossa: benign and malignant neoplasms of this “ignored” radiological anatomical space vol.44, pp.5, 2017, https://doi.org/10.1007/s00261-019-01930-7
  2. Strahlentherapie beim Analkanal- und Rektumkarzinom : Das squamöse Analkarzinom aus strahlentherapeutischer Sicht vol.41, pp.4, 2017, https://doi.org/10.1007/s00053-019-0378-5
  3. MR staging of anal cancer: what the radiologist needs to know vol.44, pp.11, 2019, https://doi.org/10.1007/s00261-019-02020-4
  4. Magnetic Resonance Imaging of the Anal Region: Clinical Applications vol.10, pp.None, 2020, https://doi.org/10.25259/jcis_180_2020
  5. Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
  6. Prognostic role of ultrasonography staging in patients with anal cancer vol.12, pp.7, 2020, https://doi.org/10.4251/wjgo.v12.i7.732
  7. A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape vol.14, pp.8, 2017, https://doi.org/10.1080/17474124.2020.1775583
  8. Cancer attributable to human papillomavirus infection in China: Burden and trends vol.126, pp.16, 2020, https://doi.org/10.1002/cncr.32986
  9. Additional Value of 2-[ 18 F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients vol.9, pp.9, 2020, https://doi.org/10.3390/jcm9092715
  10. Synchronous occurrence of HPV-associated cervical squamous cell carcinoma (FIGO IIA) in prolapsed uterus and adenocarcinoma of the anal canal cT1N0M0 : Case report vol.100, pp.50, 2021, https://doi.org/10.1097/md.0000000000028004
  11. Assessment of Apparent Diffusion Coefficients and SUVs as Predicators of Histological Differentiation in Anal Squamous Cell Carcinoma vol.46, pp.10, 2017, https://doi.org/10.1097/rlu.0000000000003795
  12. Squamous Cell Carcinoma of the Anus Incidence, Mortality, and Survival Among the General Population and Persons Living With HIV in Puerto Rico, 2000-2016 vol.7, pp.None, 2021, https://doi.org/10.1200/go.20.00299
  13. Perianal Metastasis of Small Cell Lung Carcinoma: A Case Report vol.18, pp.1, 2017, https://doi.org/10.5812/iranjradiol.110982
  14. Circulating CD14+HLA‐DRlo/− monocytic cells as a biomarker for epithelial ovarian cancer progression vol.85, pp.3, 2017, https://doi.org/10.1111/aji.13343